Could a cancer drug help cure hepatitis b? new trial launches
Disease control
Ongoing
This pilot study tests whether adding a PD-1 antibody (sintilimab) and pegylated interferon to standard antiviral therapy can help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg), a key step toward a functional cure. The trial will enroll 45 adults wh…
Phase: NA • Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC